Related Experiment Video
Updated: Feb 13, 2026
Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay
Published on: February 28, 2025
Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors
Edward C Stites1, Andrey S Shaw2
1Division of Laboratory and Genomic Medicine, Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, Missouri, USA.
Abstract:
KRAS has proven difficult to target pharmacologically. Two strategies have recently been described for covalently targeting the most common KRAS mutant in lung cancer, KRAS G12C. Previously, we developed a computational model of the processes that regulate Ras activation. Here, we use this model to investigate KRAS G12C covalent inhibitors. We updated the model to include Ras protein turnover, and validation demonstrates that our model performs well in areas of G12C targeting where conventional wisdom struggles. We then used the model to investigate possible strategies to improve KRAS G12C inhibitors and identified GEF loading as a mechanism that could improve efficacy. Our simulations also found resistance-promoting mutations may reverse which class of KRAS G12C inhibitor inhibits the system better, suggesting that there may be value to pursuing both types of KRAS G12C inhibitors. Overall, this work demonstrates areas in which systems biology approaches can inform Ras drug development.
Insights
Computational modeling advances understanding of KRAS G12C inhibitors for lung cancer. Systems biology approaches reveal GEF loading enhances efficacy and suggest pursuing dual inhibitor strategies to overcome resistance.
Area of Science:
- Oncology
- Computational Biology
- Pharmacology
Background:
- KRAS mutations are prevalent in lung cancer, presenting a significant therapeutic challenge.
- Developing targeted therapies for KRAS G12C, a common mutation, is an active area of research.
- Previous work established a computational model for Ras activation processes.
Purpose of the Study:
- To investigate KRAS G12C covalent inhibitors using an updated computational model.
- To identify strategies for improving the efficacy of KRAS G12C inhibitors.
- To explore the impact of resistance mutations on inhibitor effectiveness.
Main Methods:
- Updated a computational model of Ras activation to include Ras protein turnover.
- Validated the model's performance in KRAS G12C targeting scenarios.
- Utilized simulations to explore inhibitor improvement strategies and resistance mechanisms.
Main Results:
- The model accurately predicts outcomes in KRAS G12C targeting where traditional methods fall short.
- GEF loading was identified as a key mechanism to enhance KRAS G12C inhibitor efficacy.
- Simulations indicated that resistance mutations can alter the relative efficacy of different KRAS G12C inhibitor classes.
Conclusions:
- Systems biology modeling provides valuable insights for Ras drug development.
- Dual targeting strategies may be beneficial to overcome resistance to KRAS G12C inhibitors.
- Further research into GEF loading could optimize KRAS G12C inhibitor therapies.
Related Concept Videos
01:29Covalent Bonds
01:08Covalent Bonds
When two atoms share electrons to complete their valence shells, they create a covalent bond. An atom's electronegativity—the force with which shared electrons are pulled towards an atom—determines how the electrons are shared. Molecules formed with covalent bonds can be either polar or nonpolar. Atoms with similar electronegativities form nonpolar covalent bonds; the electrons are shared equally. Atoms with different electronegativities share electrons unequally,...
02:18Network Covalent Solids
To break or to melt a covalent network solid, covalent bonds must be broken. Because covalent bonds are relatively strong, covalent network solids are typically...
02:04Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
02:04Covalently Linked Protein Regulators
02:46Covalent Bonding and Lewis Structures